Patents by Inventor Mina Sooch

Mina Sooch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for treatment of mydriasis
    Patent number: 12201616
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: January 21, 2025
    Assignee: Opus Genetics, Inc.
    Inventors: Mina Sooch, Alan R. Meyer, Konstantinos Charizanis, Bernhard Hoffmann, William H. Pitlick
  • Methods and compositions for treatment of mydriasis
    Patent number: 12201615
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: January 21, 2025
    Assignee: Opus Genetics, Inc.
    Inventors: Mina Sooch, Alan R. Meyer, Konstantinos Charizanis, Bernhard Hoffmann, William H. Pitlick
  • Methods and compositions for treatment of glaucoma and related conditions
    Patent number: 12161629
    Abstract: Methods, compositions and kits comprising alpha-adrenergic antagonists, such as phentolamine, for the treatment of glaucoma, ocular hypertension, and/or other ocular disorders, such as non-arteritic anterior ischemic optic neuropathy or keratoconus, are provided. Said methods, compositions and kits may further comprise additional therapeutic agents, including prostaglandin analogues such as latanoprost, beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, NMDA receptor antagonist, adenosine receptor antagonists, 5-HT2a receptor agonists, or Rho kinase inhibitors.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: December 10, 2024
    Assignee: Opus Genetics, Inc.
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis
  • METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETIC RETINOPATHY AND RELATED CONDITIONS
    Publication number: 20240216315
    Abstract: The invention provides methods, compositions, and kits containing a first therapeutic agent that is a substituted 2,3-dimethoxyquinone of Formula I, or a pharmaceutically acceptable salt thereof, for treating patients suffering from diabetic retinopathy, diabetic macular edema, and/or other diabetic retinal disorders and/or other disorders.
    Type: Application
    Filed: April 29, 2022
    Publication date: July 4, 2024
    Inventors: Mina Sooch, Konstantinos Charizanis, Mark R. Kelley, Richard Adam Messmann, Mitchell George Brigell, Ronil Ajaykumar Patel
  • METHODS AND COMPOSITIONS FOR TREATING MYDRIASIS, GLAUCOMA, AND OTHER OCULARCONDITIONS
    Publication number: 20240216334
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for treating patients suffering from mydriasis, glaucoma, and other ocular conditions.
    Type: Application
    Filed: April 22, 2022
    Publication date: July 4, 2024
    Inventors: Jay Stuart PEPOSE, Eliot Stuart LAZAR, Mina SOOCH, Alan R. MEYER, Konstantinos CHARIZANIS, Bemhard HOFFMANN, William H. PITLICK
  • Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
    Patent number: 12016841
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: June 25, 2024
    Assignee: Ocuphire Pharma, Inc.
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis, Bernhard Hoffmann
  • METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS
    Publication number: 20230040217
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Application
    Filed: July 29, 2022
    Publication date: February 9, 2023
    Inventors: Mina Sooch, Alan R. Meyer, Konstantinos Charizanis, Bernhard Hoffmann, William H. Pitlick
  • METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS
    Publication number: 20230032637
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Application
    Filed: July 29, 2022
    Publication date: February 2, 2023
    Inventors: Mina Sooch, Alan R. Meyer, Konstantinos Charizanis, Bernhard Hoffmann, William H. Pitlick
  • Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
    Patent number: 11400077
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: August 2, 2022
    Assignee: Ocuphire Pharma, Inc.
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis, Bernhard Hoffmann
  • METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS
    Publication number: 20220226287
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Application
    Filed: March 30, 2022
    Publication date: July 21, 2022
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis, Bernhard Hoffmann
  • METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS
    Publication number: 20210346349
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Application
    Filed: April 14, 2021
    Publication date: November 11, 2021
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis, Bernhard Hoffmann
  • METHODS AND COMPOSITIONS FOR TREATMENT OF GLAUCOMA AND RELATED CONDITIONS
    Publication number: 20210346350
    Abstract: Methods, compositions and kits comprising alpha-adrenergic antagonists, such as phentolamine, for the treatment of glaucoma, ocular hypertension, and/or other ocular disorders, such as non-arteritic anterior ischemic optic neuropathy or keratoconus, are provided. Said methods, compositions and kits may further comprise additional therapeutic agents, including prostaglandin analogues such as latanoprost, beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, NMDA receptor antagonist, adenosine receptor antagonists, 5-HT2a receptor agonists, or Rho kinase inhibitors.
    Type: Application
    Filed: October 15, 2019
    Publication date: November 11, 2021
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis
  • Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
    Patent number: 10993932
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: May 4, 2021
    Assignee: Ocuphire Pharma, Inc.
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis, Bernhard Hoffmann
  • METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS
    Publication number: 20200253931
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Application
    Filed: April 6, 2020
    Publication date: August 13, 2020
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis, Bernhard Hoffmann
  • METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS
    Publication number: 20200246310
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Application
    Filed: April 6, 2020
    Publication date: August 6, 2020
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis, Bernhard Hoffmann
  • Methods and compositions for the inhibition of gene expression
    Publication number: 20060229267
    Abstract: The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.
    Type: Application
    Filed: June 1, 2004
    Publication date: October 12, 2006
    Inventors: Reza Sheikhnejad, Mina Sooch, Neal Goodwin, David Olson
  • Methods and compositions for the inhibition of gene expression
    Publication number: 20060198828
    Abstract: The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.
    Type: Application
    Filed: June 1, 2004
    Publication date: September 7, 2006
    Applicant: ProNAi Therapeutics, Inc.
    Inventors: Gholamreza Sheikhnejad, Mina Sooch, Neal Goodwin, David Olson
  • Methods and compositions for the inhibition of gene expression
    Publication number: 20060135455
    Abstract: The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.
    Type: Application
    Filed: June 1, 2004
    Publication date: June 22, 2006
    Inventors: Reza Sheikhnejad, Mina Sooch, Neal Goodwin, David Olson
  • Methods and compositions for the inhibition of gene expression
    Publication number: 20060073596
    Abstract: The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.
    Type: Application
    Filed: June 1, 2004
    Publication date: April 6, 2006
    Applicant: ProNAi Therapeutics, Inc.
    Inventors: Gholamreza Sheikhnehjad, Mina Sooch, Neal Goodwin, David Olson
  • Methods and compositions for the inhibition of gene expression
    Publication number: 20050287667
    Abstract: The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.
    Type: Application
    Filed: June 1, 2004
    Publication date: December 29, 2005
    Applicant: ProNAi Therapeutics, Inc.
    Inventors: Reza Sheikhnejad, Mina Sooch, Neal Goodwin, David Olson